About Astria Therapeutics
Astria Therapeutics is a company based in Boston (United States) founded in 2008 by Jill Milne was acquired by BioCryst in October 2025. It operates as a HealthTech. Astria Therapeutics has raised $196.54 million across 15 funding rounds from investors including BioCryst, HHS and Perceptive Advisors. The company has 78 employees as of December 31, 2024. Astria Therapeutics has completed 1 acquisition, including Quellis Biosciences. Astria Therapeutics offers products and services including Navenibart (STAR-0215) and STAR-0310. Astria Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
- Headquarter Boston, United States
- Employees 78 as on 31 Dec, 2024
- Founders Jill Milne
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Astria Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$94.26 M (USD)-29.32as on Dec 31, 2024
-
EBITDA
-$111.56 M (USD)-64.46as on Dec 31, 2024
-
Total Equity Funding
$196.54 M (USD)
in 15 rounds
-
Latest Funding Round
$110.01 M (USD), Post-IPO
Jan 29, 2021
-
Investors
BioCryst
& 4 more
-
Employee Count
78
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
BioCryst
(Oct 17, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Astria Therapeutics
Astria Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ATXS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Astria Therapeutics
Astria Therapeutics offers a comprehensive portfolio of products and services, including Navenibart (STAR-0215) and STAR-0310.
Developed for treating Hereditary Angioedema in patients.
Designed for managing Atopic Dermatitis in patients.
People of Astria Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Astria Therapeutics
Astria Therapeutics has successfully raised a total of $196.54M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $110.01 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Astria Therapeutics
Astria Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include BioCryst, HHS and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Astria Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Astria Therapeutics
Astria Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quellis Biosciences.
Investment portfolio details for Astria Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody-based therapeutics for rare diseases are developed and optimized.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Astria Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Astria Therapeutics
Detailed financials for Astria Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Astria Therapeutics Comparisons
Peer comparison for Astria Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Astria Therapeutics
Astria Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Astria Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Astria Therapeutics
Complete news archive for Astria Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Astria Therapeutics
Astria Therapeutics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Astria Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jill Milne is the current CEO of Astria Therapeutics. They have also founded this company.
Astria Therapeutics is a funded company, having raised a total of $196.54M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Astria Therapeutics is 78.
Astria Therapeutics is engaged in the development of life-changing therapies for patients and families affected by allergic and immunologic diseases. The company is dedicated to addressing unmet needs in therapeutic areas such as Hereditary Angioedema and Atopic Dermatitis. Solutions like Navenibart (STAR-0215) and STAR-0310 are being developed through clinical trials to provide innovative treatment options. The organization is guided by patient stories and community feedback to shape its scientific and therapeutic advancements. Sectors of focus include biotechnology and healthcare, with an emphasis on transparency and trust-building with stakeholders.
Astria Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Astria Therapeutics offers Navenibart (STAR-0215) and STAR-0310.
Yes, Astria Therapeutics is publicly traded on NASDAQ under the ticker symbol ATXS.
Astria Therapeutics has made 1 acquisition, including Quellis Biosciences.
Astria Therapeutics has 5 investors. Key investors include BioCryst, HHS, Perceptive Advisors, Lightstone Ventures, and MedImmune Ventures.
The ticker symbol of Astria Therapeutics is ATXS on NASDAQ.